Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi 305: tarlatamab + durvalumab versus durvalumab maintenance in first-line extensive-stage small cell lung cancer
NL-OMON60974Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Dec 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of tarlatamab and durvalumab in small cell lung cancer (SCLC), sponsored by Amgen. Primary endpoint: Overall survival. Started Dec 2024; status: active, not recruiting.
02
Drugs
tarlatamabdurvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON60974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60974.